Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
– Clinical milestone marks initiation of first ever novel psilocybin analog to enter clinical development – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for … [Read more…]
